{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-073998","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2026-07-01T12:05:36+00:00","discovered_at":"2026-07-01T12:10:00.387155+00:00","generated_at":"2026-07-01T12:11:07.904023+00:00","sec_items":["5.07","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Allarity Therapeutics granted U.S. patent for stenoparib DRP companion diagnostic through April 2042","bullets":["USPTO granted key U.S. patent covering stenoparib-specific Drug Response Predictor (DRP) companion diagnostic.","Patent term extends into April 2042, providing long-term exclusivity for stenoparib when used with the DRP test.","Patent covers methods to predict clinical benefit from stenoparib based on tumor gene-expression profiles and patient selection.","Allarity also has patent protection for stenoparib DRP in Europe and Australia into 2039."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-073998","json":"https://secwatch.observer/filing/0001213900-26-073998.json","markdown":"https://secwatch.observer/filing/0001213900-26-073998.md","text":"https://secwatch.observer/filing/0001213900-26-073998.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000121390026073998/0001213900-26-073998-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000121390026073998/ea0296615-8k_allarity.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-01T12:11:07.904023+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}